What Trump’s FTC picks mean for biopharma dealmaking and PBMs

Jared Whitlock

Features Editor

President-elect Donald Trump’s two picks for the Federal Trade Commission are likely to usher in more life sciences deals while maintaining the agency’s pressure on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

What Trump’s FTC picks mean for biopharma dealmaking and PBMs

Jared Whitlock

Features Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Sage sues Biogen days after $469M buyout offer

FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit

Novo claims high-dose Phase 3 Wegovy win but sales impact might be muted

Ozempic makes list for next round of Medicare drug price negotiations

Roche's cardiometabolic chief warns against weight loss 'obsession' with GLP-1s

Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Features Editor

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

What Trump’s FTC picks mean for biopharma dealmaking and PBMs